Bio Green Med Solution, Inc.
BGMS Healthcare Biotechnology
Bio Green Med Solution, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747,000.00, up 1,637.2% from fiscal 2024. In the quarter to June 2026, revenue grew 3,260.0%, EPS grew 91.8% and free cash flow grew 66.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BGMS
Bio Green Med Solution, Inc. (BGMS) EV/Sales
As of 16 October 2026, Bio Green Med Solution, Inc. (BGMS) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −25.9× (June 2025) to 18,487,767× (March 2015); the current reading is higher than 72% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.4× | — |
| FY2024 | −14.9× | — |
| FY2023 | −1.7× | — |
| FY2018 | −10.3× | — |
| FY2016 | −19.6× | — |
| FY2015 | −10.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | (49.23%) |
| Mar 2026 | 1.4× | — |
| Dec 2025 | −0.4× | — |
| Sep 2025 | 45.2× | (56.17%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | −352× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | −40.1× |
| CANF Can-Fite Biopharma Ltd compare | −8.6× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| BGMS Bio Green Med Solution, Inc. | 0.7× |
| PULM Pulmatrix, Inc. compare | 0.8× |
| IMNN Imunon, Inc. compare | 8.0× |
| ORGS Orgenesis Inc. compare | 15.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)